Melanoma Testing Guidelines

· Which patients to test:

· Metastatic disease (NCCN)

· Which specimen to test:

· Metastatic tumour is preferred over primary tumour if a choice is available (NCCN)

· Which tests to perform:

· BRAF mutations (V600; specific alteration not specified in 2018 NCCN) (c.1799 specified in colorectal 2017)

· Likely to respond to BRAF inhibitors

· MEK inhibitors may potentiate the response

· KIT mutations (activating)

· More likely to respond to imatinib

· 20-30% overall response rate

·